Evaluation of the Impact of the Clinical Pharmacist in Oral Therapies in Oncology.
ConditionNeoplasm
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPolyclinique Lyon Nord
About this trial
The hospital pharmacist plays a vital role at the time of the patient's first prescription in a healthcare facility, to inform the patient about his or her new therapy and create a link between the hospital and the patient's home pharmacy, so that the patient can continue to receive care at home. It is also essential that the hospital pharmacy and the patient's local pharmacy work together within a reasonable timeframe. This will help improve patient care and treatment follow-up, detect any undesirable effects and optimize their management..
The aim of this prospective interventional study is to measure the benefits of pharmaceutical monitoring in healthcare institutions at the initiation of oral therapy on patient compliance, side-effect management and adherence, in comparison with patients without this monitoring.
The primary endpoint is compliance with the Girerd questionnaire.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient suffering from an oncological pathology (excluding hematological malignancies)
Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments).
Patient who has not yet started treatment or who has started treatment less than 30 days
Patient with continuation of oral therapy dispensed in pharmacies
Disqualifiers
Patients suffering from hematological malignancies
Patient living in an institution or hospital
Patient under treatment for more than 30 days
Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment)
Trial design
Design model
Parallel
Treatments tested in this trial
Pharmaceutical consultation
Procedure/SurgeryThe pharmaceutical interview is a structured way of carrying out an optimized medication review with the patient. This interview takes place at the time of the first prescription of oral anti-cancer treatment.
Pharmaceutical consultation and follow-up
Procedure/SurgeryAfter the first prescription and at the treatment renewal date (+/- 2 days), the hospital pharmacist will contact the dispensing pharmacist to inform him/her of the patient's treatment, and then as part of the follow-up to detect any problems with treatment compliance (non-renewal of treatment by the patient, lack of follow-up, complaints of adverse effects by the patient). These events will be recorded in the observation book.
Treatment groups
90 Participants
are divided into 2 treatment groupsGroup A: specialized pharmaceutical consultation and follow-up in hospitals and community pharmaciesExperimental treatment 1 intervention
Group B: specialized pharmaceutical consultationActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Observance
The measurement of the primary endpoint is based on the use of a validated scale for assessing medication compliance: the Girerd scale. This is a 6-question questionnaire with a binary yes/no response. The score ranges from 0 to 6, with a "yes" worth 1 point.
Time frame
3 months and 6 months after treatment initiationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov